Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination

Ryousuke Koike, Michiru Sawahata, Yosikazu Nakamura, Yushi Nomura, Otohiro Katsube, Koichi Hagiwara, Seiji Niho, Norihiro Masuda, Takaaki Tanaka, Kumiya Sugiyama
doi: https://doi.org/10.1101/2022.01.23.22269706
Ryousuke Koike
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michiru Sawahata
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
3Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sawahata@jichi.ac.jp
Yosikazu Nakamura
4Department of Public Health, Jichi Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yushi Nomura
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otohiro Katsube
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koichi Hagiwara
3Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiji Niho
2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norihiro Masuda
5Department of Surgery, National Hospital Organization Utsunomiya National Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takaaki Tanaka
6Department of Orthopaedic Surgery, National Hospital Organization Utsunomiya National Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumiya Sugiyama
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
7Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective We aimed to determine the relationship between vaccine-related adverse effects and antibody (Ab) titers from 3 to 6 months after the second dose of the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine (Pfizer/BioNTech) in Japan.

Methods We enrolled 378 healthcare workers (255 women, 123 men) whose Ab titers 3 and 6 months after the second dose were analyzed in our previous study and whose characteristics and adverse effects were collected previously using a structured self-report questionnaire.

Results Median age was 44 years. While injection-site symptoms occurred with almost equal frequency between the first and second doses, systemic adverse effects, such as general fatigue and fever, were significantly more frequent after the second dose than after the first. Multivariate analysis showed that fever was significantly correlated with female sex for the second dose (odds ratio [OR], 2.139; 95% confidence interval [95%CI], 1.185–3.859), older age for the first dose (OR, 0.962; 95%CI, 0.931–0.994) and second dose (OR, 0.957; 95%CI, 0.936–0.979), and dyslipidemia for the first dose (OR, 8.750; 95%CI, 1.814–42.20). Age-adjusted Ab titers at 3 months after vaccination were 23.7% and 23.4% higher in patients with fever than in those without fever after first and second dose, respectively. In addition, age-adjusted Ab titers at 3 and 6 months after the second dose were respectively 21.7% and 19.3% higher in the group with anti-inflammatory agent use than in the group without anti-inflammatory agent use.

Conclusion Participants with systemic adverse effects tend to have higher Ab titers from 3 to 6 months after the second dose of the BNT162b2 vaccine. Our results may encourage vaccination, even among people with vaccine hesitancy related to relatively common systemic adverse effects.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any external funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics Committee of National Hospital Organization Utsunomiya National Hospital (No. 03-01; April 19, 2021) approved this study

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

  • Abbreviations

    COVID-19
    coronavirus disease 2019
    Ab
    antibody
    SARS-CoV-2
    severe acute respiratory syndrome coronavirus 2
    ECLIA
    electrochemiluminescence immunoassay
    IQR
    interquartile range
    OR
    odds ratio
    CI
    confidence interval
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted January 24, 2022.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination
    Ryousuke Koike, Michiru Sawahata, Yosikazu Nakamura, Yushi Nomura, Otohiro Katsube, Koichi Hagiwara, Seiji Niho, Norihiro Masuda, Takaaki Tanaka, Kumiya Sugiyama
    medRxiv 2022.01.23.22269706; doi: https://doi.org/10.1101/2022.01.23.22269706
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination
    Ryousuke Koike, Michiru Sawahata, Yosikazu Nakamura, Yushi Nomura, Otohiro Katsube, Koichi Hagiwara, Seiji Niho, Norihiro Masuda, Takaaki Tanaka, Kumiya Sugiyama
    medRxiv 2022.01.23.22269706; doi: https://doi.org/10.1101/2022.01.23.22269706

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (162)
    • Allergy and Immunology (416)
    • Anesthesia (91)
    • Cardiovascular Medicine (863)
    • Dentistry and Oral Medicine (159)
    • Dermatology (98)
    • Emergency Medicine (251)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
    • Epidemiology (8571)
    • Forensic Medicine (4)
    • Gastroenterology (388)
    • Genetic and Genomic Medicine (1759)
    • Geriatric Medicine (167)
    • Health Economics (373)
    • Health Informatics (1249)
    • Health Policy (622)
    • Health Systems and Quality Improvement (468)
    • Hematology (196)
    • HIV/AIDS (378)
    • Infectious Diseases (except HIV/AIDS) (10318)
    • Intensive Care and Critical Care Medicine (553)
    • Medical Education (192)
    • Medical Ethics (51)
    • Nephrology (213)
    • Neurology (1682)
    • Nursing (97)
    • Nutrition (252)
    • Obstetrics and Gynecology (328)
    • Occupational and Environmental Health (451)
    • Oncology (930)
    • Ophthalmology (264)
    • Orthopedics (102)
    • Otolaryngology (172)
    • Pain Medicine (114)
    • Palliative Medicine (40)
    • Pathology (253)
    • Pediatrics (538)
    • Pharmacology and Therapeutics (254)
    • Primary Care Research (209)
    • Psychiatry and Clinical Psychology (1775)
    • Public and Global Health (3853)
    • Radiology and Imaging (626)
    • Rehabilitation Medicine and Physical Therapy (320)
    • Respiratory Medicine (521)
    • Rheumatology (208)
    • Sexual and Reproductive Health (168)
    • Sports Medicine (158)
    • Surgery (191)
    • Toxicology (36)
    • Transplantation (101)
    • Urology (76)